(TSLA) Tesla - Overview
Stock: Electric Vehicles, Energy Storage, Solar Panels
| Risk 5d forecast | |
|---|---|
| Volatility | 44.4% |
| Relative Tail Risk | -5.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.76 |
| Alpha | 7.08 |
| Character TTM | |
|---|---|
| Beta | 1.938 |
| Beta Downside | 1.504 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.77% |
| CAGR/Max DD | 0.52 |
EPS (Earnings per Share)
Revenue
Risks
P/E ratio: 385.4529
Description: TSLA Tesla March 02, 2026
Tesla, Inc. (NASDAQ: TSLA) designs, manufactures and sells electric vehicles (EVs) and energy-generation and storage products across the United States, China and other international markets. The firm operates two primary segments – Automotive and Energy Generation & Storage – and monetises its ecosystem through vehicle sales, regulatory-credit sales, financing, insurance, after-market services, Supercharger access and a growing portfolio of solar and battery solutions.
In the most recent quarter (Q4 2025), Tesla delivered ≈ 1.9 million vehicles worldwide, posting an automotive gross margin of 18.5 % and generating $5.5 billion of free cash flow. Energy storage deployments rose to 2.5 GWh, while solar installations reached 1.2 GW, reflecting continued demand for integrated renewable-energy solutions. These results are underpinned by a 12 % YoY decline in lithium-ion battery costs to roughly $80/kWh and a 9 % increase in global EV registrations, both of which bolster Tesla’s pricing power and market share expansion.
Key macro drivers include tightening emissions regulations in Europe and China, sustained U.S. federal tax credits for EV purchases, and a broader shift toward on-site renewable generation by commercial customers seeking resilience against volatile energy prices.
For a deeper, data-rich analysis of Tesla’s valuation dynamics, you might explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 3.79b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.58 > 1.0 |
| NWC/Revenue: 38.94% < 20% (prev 30.24%; Δ 8.71% < -1%) |
| CFO/TA 0.11 > 3% & CFO 14.75b > Net Income 3.79b |
| Net Debt (-8.14b) to EBITDA (11.76b): -0.69 < 3 |
| Current Ratio: 2.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.54b) vs 12m ago 0.63% < -2% |
| Gross Margin: 18.03% > 18% (prev 0.18%; Δ 1785 % > 0.5%) |
| Asset Turnover: 72.98% > 50% (prev 80.03%; Δ -7.05% > 0%) |
| Interest Coverage Ratio: 16.62 > 6 (EBITDA TTM 11.76b / Interest Expense TTM 338.0m) |
Altman Z'' 3.72
| A: 0.27 (Total Current Assets 68.64b - Total Current Liabilities 31.71b) / Total Assets 137.81b |
| B: 0.28 (Retained Earnings 39.00b / Total Assets 137.81b) |
| C: 0.04 (EBIT TTM 5.62b / Avg Total Assets 129.94b) |
| D: 0.72 (Book Value of Equity 39.37b / Total Liabilities 54.94b) |
| Altman-Z'' Score: 3.72 = AA |
Beneish M -2.45
| DSRI: 1.07 (Receivables 4.58b/4.42b, Revenue 94.83b/97.69b) |
| GMI: 0.99 (GM 18.03% / 17.86%) |
| AQI: 2.07 (AQ_t 0.21 / AQ_t-1 0.10) |
| SGI: 0.97 (Revenue 94.83b / 97.69b) |
| TATA: -0.08 (NI 3.79b - CFO 14.75b) / TA 137.81b) |
| Beneish M-Score: -2.45 (Cap -4..+1) = BBB |
What is the price of TSLA shares?
Over the past week, the price has changed by -4.14%, over one month by -7.00%, over three months by -12.16% and over the past year by +37.86%.
Is TSLA a buy, sell or hold?
- StrongBuy: 14
- Buy: 7
- Hold: 16
- Sell: 3
- StrongSell: 7
What are the forecasts/targets for the TSLA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 421.7 | 7.5% |
| Analysts Target Price | 421.7 | 7.5% |
TSLA Fundamental Data Overview February 28, 2026
P/E Forward = 200.0
P/S = 16.1681
P/B = 19.0689
P/EG = 6.1651
Revenue TTM = 94.83b USD
EBIT TTM = 5.62b USD
EBITDA TTM = 11.76b USD
Long Term Debt = 6.58b USD (from longTermDebt, last quarter)
Short Term Debt = 1.64b USD (from shortTermDebt, last quarter)
Debt = 8.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -8.14b USD (from netDebt column, last quarter)
Enterprise Value = 1539.65b USD (1533.17b + Debt 8.38b - CCE 1.89b)
Interest Coverage Ratio = 16.62 (Ebit TTM 5.62b / Interest Expense TTM 338.0m)
EV/FCF = 247.5x (Enterprise Value 1539.65b / FCF TTM 6.22b)
FCF Yield = 0.40% (FCF TTM 6.22b / Enterprise Value 1539.65b)
FCF Margin = 6.56% (FCF TTM 6.22b / Revenue TTM 94.83b)
Net Margin = 4.00% (Net Income TTM 3.79b / Revenue TTM 94.83b)
Gross Margin = 18.03% ((Revenue TTM 94.83b - Cost of Revenue TTM 77.73b) / Revenue TTM)
Gross Margin QoQ = 20.12% (prev 17.99%)
Tobins Q-Ratio = 11.17 (Enterprise Value 1539.65b / Total Assets 137.81b)
Interest Expense / Debt = 1.01% (Interest Expense 85.0m / Debt 8.38b)
Taxrate = 27.52% (325.0m / 1.18b)
NOPAT = 4.07b (EBIT 5.62b * (1 - 27.52%))
Current Ratio = 2.16 (Total Current Assets 68.64b / Total Current Liabilities 31.71b)
Debt / Equity = 0.10 (Debt 8.38b / totalStockholderEquity, last quarter 82.14b)
Debt / EBITDA = -0.69 (Net Debt -8.14b / EBITDA 11.76b)
Debt / FCF = -1.31 (Net Debt -8.14b / FCF TTM 6.22b)
Total Stockholder Equity = 78.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.92% (Net Income 3.79b / Total Assets 137.81b)
RoE = 4.83% (Net Income TTM 3.79b / Total Stockholder Equity 78.52b)
RoCE = 6.60% (EBIT 5.62b / Capital Employed (Equity 78.52b + L.T.Debt 6.58b))
RoIC = 4.73% (NOPAT 4.07b / Invested Capital 85.97b)
WACC = 12.99% (E(1533.17b)/V(1541.54b) * Re(13.06%) + D(8.38b)/V(1541.54b) * Rd(1.01%) * (1-Tc(0.28)))
Discount Rate = 13.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.67%
[DCF] Terminal Value 59.36% ; FCFF base≈5.16b ; Y1≈4.59b ; Y5≈3.83b
[DCF] Fair Price = 11.69 (EV 35.73b - Net Debt -8.14b = Equity 43.86b / Shares 3.75b; r=12.99% [WACC]; 5y FCF grow -13.76% → 2.90% )
EPS Correlation: -71.21 | EPS CAGR: -18.36% | SUE: 0.31 | # QB: 0
Revenue Correlation: 52.52 | Revenue CAGR: 7.85% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.46 | Chg7d=+0.000 | Chg30d=-0.029 | Revisions Net=-4 | Analysts=21
EPS current Year (2026-12-31): EPS=2.06 | Chg7d=+0.000 | Chg30d=-0.116 | Revisions Net=-9 | Growth EPS=+23.9% | Growth Revenue=+8.5%
EPS next Year (2027-12-31): EPS=2.80 | Chg7d=+0.000 | Chg30d=-0.201 | Revisions Net=-14 | Growth EPS=+36.3% | Growth Revenue=+17.1%
[Analyst] Revisions Ratio: -0.50 (2 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 12.8% (Discount Rate 13.1% - Earnings Yield 0.3%)
[Growth] Growth Spread = -2.4% (Analyst 10.4% - Implied 12.8%)